3 Stocks I'm Not Selling No Matter What the Market Does

The article recommends holding Medtronic, Realty Income, and Nucor through a likely future bear market, highlighting dividend yields of 3.5%, 5.2%, and 0.9%, respectively. Medtronic has 49 straight years of dividend increases, Realty Income has raised its dividend for 31 years and maintained above-96% occupancy during the Great Recession, and Nucor is a Dividend King with over 50 consecutive annual hikes. The piece is mainly a defensive, long-term stock selection commentary rather than a catalyst-driven news event.

Analysis

This reads as a defensive-duration trade masquerading as a dividend note: the common thread is balance-sheet resilience plus cash-return visibility, not yield alone. If rates stay elevated or drift higher, the market will keep rewarding businesses whose dividend growth is funded internally and penalizing payout stories that depend on multiple expansion; that makes MDT the cleanest relative-value expression here because it combines defensive healthcare demand with a still-repairing operating model. O looks more like a financing-rate beneficiary only if long rates stabilize; if cap rates reprice another 50-75 bps higher, the market will likely keep discounting FFO growth even if occupancy holds up.

The second-order winner is Nucor’s industrial flexibility, but the stock is already pricing a benign midcycle, so it becomes less of a “quality compounder” and more of a volatility hedge on a recession scare. In a true downturn, the equity can underperform for several quarters even while the business outlasts peers, which means timing matters more than conviction. The better trade is not to chase the stock here, but to own it only as a dislocation buy if steel prices, auto/build activity, or PMI data roll over and the market starts pricing a supply discipline cycle.

Contrarian angle: the consensus is overpaying for the idea that dividend durability automatically equals downside protection. In a sharp bear market, all three names can de-rate simultaneously because they are crowded into the same “quality income” bucket, even though their fundamentals differ materially. The real edge is to separate cash-yield stability from price stability: MDT offers the best asymmetry, O offers the most rate sensitivity, and NUE offers the best eventual rebound but the weakest near-term carry.

Key Decisions for Investors

• Go long MDT on a 1-3 month horizon into any post-earnings pullback; target a 10-15% total return if the market continues to reward defensive healthcare plus operating improvement, with downside limited by yield support and dividend credibility.
• Hold O only as a rates hedge and avoid adding ahead of sticky CPI / higher-for-longer Fed prints; if the 10-year Treasury pushes materially above recent ranges, expect another 5-10% equity drawdown from cap-rate pressure.
• Stage a buy-wishlist order in NUE only on cyclical weakness tied to PMI/industrial slowdown; the risk/reward improves materially if the stock falls 15-20% on recession fears while the dividend remains covered.
• Pair trade: long MDT / short a higher-beta healthcare or consumer staple income proxy for 3-6 months; thesis is that quality earnings momentum should outperform pure yield in a choppy tape.
• Avoid a basket long of all three as a single 'defensive dividend' trade; the hidden risk is common factor exposure to rates and risk-off de-rating, which can swamp stock-specific quality in the first leg of a bear market.